ZA952269B - Antibody conjugates with improved properties - Google Patents

Antibody conjugates with improved properties

Info

Publication number
ZA952269B
ZA952269B ZA952269A ZA952269A ZA952269B ZA 952269 B ZA952269 B ZA 952269B ZA 952269 A ZA952269 A ZA 952269A ZA 952269 A ZA952269 A ZA 952269A ZA 952269 B ZA952269 B ZA 952269B
Authority
ZA
South Africa
Prior art keywords
improved properties
antibody conjugates
conjugates
antibody
properties
Prior art date
Application number
ZA952269A
Other languages
English (en)
Inventor
Brendan Murray
Terence O'reilly
Gerd Pluschke
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA952269B publication Critical patent/ZA952269B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA952269A 1994-03-21 1995-03-20 Antibody conjugates with improved properties ZA952269B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810173 1994-03-21

Publications (1)

Publication Number Publication Date
ZA952269B true ZA952269B (en) 1995-09-21

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952269A ZA952269B (en) 1994-03-21 1995-03-20 Antibody conjugates with improved properties

Country Status (11)

Country Link
JP (1) JPH0820545A (xx)
KR (1) KR950031111A (xx)
AU (1) AU1481795A (xx)
CA (1) CA2144936A1 (xx)
FI (1) FI951276A (xx)
HU (1) HUT71776A (xx)
IL (1) IL113022A (xx)
NO (1) NO951061L (xx)
NZ (1) NZ270734A (xx)
RU (1) RU95104325A (xx)
ZA (1) ZA952269B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible

Also Published As

Publication number Publication date
RU95104325A (ru) 1996-12-27
KR950031111A (ko) 1995-12-18
FI951276A (fi) 1995-09-22
IL113022A0 (en) 1995-06-29
IL113022A (en) 2000-02-29
CA2144936A1 (en) 1995-09-22
AU1481795A (en) 1995-09-28
NO951061D0 (no) 1995-03-20
FI951276A0 (fi) 1995-03-17
HU9500586D0 (en) 1995-04-28
JPH0820545A (ja) 1996-01-23
HUT71776A (en) 1996-01-29
NO951061L (no) 1995-09-22
NZ270734A (en) 1997-05-26

Similar Documents

Publication Publication Date Title
GB9422383D0 (en) Antibodies
TJ328B (en) Interferron conjugates
PL330111A1 (en) Concentyratyed antibody preparation
EP1073464A4 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
GB9603256D0 (en) Antibodies
GB9809839D0 (en) Antibody
EP0765166A4 (en) RADIOACTIVELY MARKED ANNEXIN GALACTOSE CONJUGATES
IL116456A0 (en) Oligonucleotide-dendrimer conjugates
GB9828700D0 (en) Antibody
IL113022A (en) Antibody conjugates with improved properties
IL98777A0 (en) Antibody conjugates
GB9419256D0 (en) Antibody and conjugates
ZA9510827B (en) Oligonucleotide-dendrimer conjugates
HU9501990D0 (en) Rapamycin conjugates and antibodies
GB9021210D0 (en) Antigen-antibody conjugates
ZA954678B (en) Monoclonal antibody against cd44v6
GB9406243D0 (en) Antibodies
IL134049A0 (en) Anti-cryptdin antibodies
GB9406222D0 (en) Huminised antibodies
GB9415331D0 (en) Antibodies
GB9406244D0 (en) Altered antibodies
GB9401597D0 (en) Altered antibodies
GB9404300D0 (en) Antibodies with improved effector function
GB9110444D0 (en) Antigen-antibody conjugates ii
GB9402593D0 (en) Antibody fragments